The Gene Amplification Technologies Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

A Rise in Demand for Genetic Data Collecting to Identify and Map Every Gene in the Human Genome Is Causing the Global Market to Expand
Gene amplification is the differential expansion of a certain region of the genome relative to the rest. Most species appear to engage in this process, which has been demonstrated to take place in both somatic and germline cells. Gene Amplification can have positive such as a growth or survival benefit or negative effects on the organism. It can be linked to normal developmental processes or occur as spontaneous genetic events. Somatic cell gene amplification in human malignancies has lately received substantial research. Proto-oncogene amplifica...

Gene therapies will provide a valid treatment option for patients that have developed resistance to chemotherapies across several cancer indications. With patient access set to increase over the next decade, these therapies are expected to eliminate the need for further treatments and reduce the cost of disease management. Total sales of in-vivo gene therapies are forecast to reach over $7bn by 2027 across the 8MM*, with the therapeutic oligonucleotide market forecast to reach $4.5bn by 2027 globally.

Scope

Overview of gene therapy including classification of therapy and technologies, regulatory and market access details, product & company profiles. Quotes from US- and 5EU-based key opinion leaders and researchers. Key topics covered for gene therapy in oncology in the 8MM include trends, value chain, market analysis, opportunities, challenges and unmet needs and high-value deals. Pipeline analysis: Comprehensive data split across different phases and indications, emerging novel trends under development, and analysis of the most promising late-stage pipeline drug...

Summary

Gene therapies have been a point of discussion during the last several years as a potential curative option for a variety of disease indications. While mainly still in preclinical stages, gene therapy aims to treat or alleviate a disease by genetically modifying the cells of a patient. This report focuses on gene therapies in development across the 8MM for cardiovascular and metabolic disorders, including coronary artery disease, critical limb ischemia, diabetic foot ulcers, and Pompe Disease. In addition, this report provides an assessment of the pipeline, clinical, and commercial landscape of gene therapies in CVMD supplemented with a variety of KOL and payer perspectives.

Scope

This report combines KOL and Payer insights along with data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -
- Overview of CVMD and Gene Therapies: epidemiology and regulatory oversight
- Pipeline Assessment: regional breakdown, promis...

Summary

Global Markets Direct’s, ‘Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Pipeline Review, H2 2016’, provides in depth analysis on Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted pipeline therapeutics.

The report provides comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s r...

Summary

Global Markets Direct’s, ‘Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2016’, provides in depth analysis on Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted pipeline therapeutics.

The report provides comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 i...

Summary

Global Markets Direct’s, ‘Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H1 2016’, provides in depth analysis on Calcitonin Gene Related Peptide (CGRP) targeted pipeline therapeutics.

The report provides comprehensive information on the Calcitonin Gene Related Peptide (CGRP), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databa...